ClinicalTrials.gg
CompletedNCT00094107Updated Jun 26, 2012Results posted

Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma

A Phase 2 interventional study of Axitinib [AG-013736] in Melanoma and Skin Neoplasms, sponsored by Pfizer. Completed at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-26.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies in Melanoma by Pfizer — 1 open to participants now, 4 under way, 1 of them phase 3. Melanoma · Pfizer.

Enrollment
33rd of 48
32 · median 77
Started
2004
with 2 others
Phase 2
13 of 52
none open now
Registered
4th of 52
by date

Among the 52 studies in Melanoma by Pfizer, this one is the 33rd largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2004, is one of 13 in phase 2, and was the 4th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

1 of the 52 studies in Melanoma by Pfizer is open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Melanoma by Pfizer, or all of them as a file.
02

Study summary

This is a Phase 2 study being conducted at multiple centers in the United States and France. Patients having melanoma that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that has been treated with no more than 1 prior treatment for metastatic disease (prior adjuvant treatment for localized disease does not count as prior treatment for metastatic disease). The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for metastatic melanoma as shown by the number of patients in the study who experience significant and durable tumor shrinkage.

03

Conditions studied

  • Melanoma
  • Skin Neoplasms

Keywords

  • melanoma
  • antiangiogenesis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented melanoma with
  • No more than 1 prior systemic therapy for metastatic disease (prior therapy with interferon does not count as prior therapy for metastatic disease)

Exclusion criteria

Exclusion Criteria:

  • History of hemoptysis (coughing up of blood)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Axitinib [AG-013736]

    Drug: Axitinib [AG-013736]

Interventions

  • VEGFR \[vascular endothelial growth factor Receptor\] and PDGFR \[Platelet-Derived Growth Factor Receptor\] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response (OR)

    Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 147 weeks

Secondary outcomes

  1. Progression-free Survival (PFS)

    Time in days from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

    Time frame: Baseline until the date of first documented progression or death due to any cause, assessed every 8 weeks up to 147 weeks

  2. Duration of Response (DR)

    Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

    Time frame: Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 147 weeks

  3. Overall Survival (OS)

    Time in days from the start of study treatment to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.

    Time frame: Baseline to death due to any cause or at least 1 year after the initial dose for the last treated participant

Other outcomes

  1. Population Pharmacokinetics for Axitinib (AG-013736) Plasma Concentrations

    Population pharmacokinetic analysis involved mixed effects modeling using nonlinear mixed effects modeling (NONMEM) software. The intent of this analysis was to establish a basic population pharmacokinetic model for axitinib (AG-013736) and to determine inter-individual and residual variability in population (oral) clearance, and volume of distribution of drug. Relationship of demographic variables (gender, age, body weight, height and ethnicity), concomitant medications and measures of altered hepatic and renal function were examined by fitting measured axitinib (AG-013736) concentrations.

    Time frame: Day 1 (pre-dose), Day 29, Day 57 and then every 8 weeks up to 147 weeks

  2. Plasma Concentrations of Soluble Proteins

    Plasma concentrations of soluble proteins (vascular endothelial growth factor \[VEGF\], placental growth factor \[PlGF\] and soluble vascular endothelial growth factor receptor-2 \[sVEGFR2\]) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.

    Time frame: Day 1 (pre-dose) and then every 8 weeks up to 147 weeks

07

Results

Posted Mar 30, 2012
Limitations and caveats
Population pharmacokinetic and plasma concentrations of soluble proteins were not presented, as the data was not available for the single study and data for all the axitinib (AG-013736) Phase 2 studies would be pooled together in a separate report.

Participant flow

Participant flow — Overall Study
MilestoneAxitinib
Started32
Completed0
Not completed32
Withdrew: Lack of efficacy23
Withdrew: Death5
Withdrew: Adverse event3
Withdrew: Withdrawal due to disease progression1

Outcome measures

PrimaryPercentage of Participants With Objective Response (OR)

Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 147 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (OR)
Percentage of participantsAxitinib
Percentage of Participants With Objective Response (OR)18.8 (7.2 to 36.4)
SecondaryProgression-free Survival (PFS)

Time in days from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

Time frame:
Baseline until the date of first documented progression or death due to any cause, assessed every 8 weeks up to 147 weeks
Reported as:
Median · Days
Progression-free Survival (PFS)
DaysAxitinib
Progression-free Survival (PFS)117.5 (69.0 to 204.0)
SecondaryDuration of Response (DR)

Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame:
Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 147 weeks
Reported as:
Median · Days
Duration of Response (DR)
DaysAxitinib
Duration of Response (DR)179.0 (151.0 to 516.0)
SecondaryOverall Survival (OS)

Time in days from the start of study treatment to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.

Time frame:
Baseline to death due to any cause or at least 1 year after the initial dose for the last treated participant
Reported as:
Median · Days
Overall Survival (OS)
DaysAxitinib
Overall Survival (OS)200.5 (157.0 to 274.0)
Other pre-specifiedPopulation Pharmacokinetics for Axitinib (AG-013736) Plasma Concentrations

Population pharmacokinetic analysis involved mixed effects modeling using nonlinear mixed effects modeling (NONMEM) software. The intent of this analysis was to establish a basic population pharmacokinetic model for axitinib (AG-013736) and to determine inter-individual and residual variability in population (oral) clearance, and volume of distribution of drug. Relationship of demographic variables (gender, age, body weight, height and ethnicity), concomitant medications and measures of altered hepatic and renal function were examined by fitting measured axitinib (AG-013736) concentrations.

Time frame:
Day 1 (pre-dose), Day 29, Day 57 and then every 8 weeks up to 147 weeks
Reported as:
Mean · ng/mL

No measurements were reported for this outcome.

Other pre-specifiedPlasma Concentrations of Soluble Proteins

Plasma concentrations of soluble proteins (vascular endothelial growth factor \[VEGF\], placental growth factor \[PlGF\] and soluble vascular endothelial growth factor receptor-2 \[sVEGFR2\]) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.

Time frame:
Day 1 (pre-dose) and then every 8 weeks up to 147 weeks
Reported as:
Mean · Ratio

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib—18/32 (56.3%)32/32 (100%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventAxitinib
General physical health deteriorationGeneral disorders2/32
DehydrationMetabolism and nutrition disorders2/32
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/32
Atrial fibrillationCardiac disorders1/32
Atrial tachycardiaCardiac disorders1/32
Cardiac arrestCardiac disorders1/32
Abdominal pain, not otherwise specified (NOS)Gastrointestinal disorders1/32
Intestinal perforation NOSGastrointestinal disorders1/32
Disease progression NOSGeneral disorders1/32
FatigueGeneral disorders1/32
Most frequent other events
Showing 10 of 161
Most frequent other events
EventAxitinib
FatigueGeneral disorders20/32
HypertensionVascular disorders14/32
NauseaGastrointestinal disorders13/32
DysphoniaRespiratory, thoracic and mediastinal disorders12/32
DiarrhoeaGastrointestinal disorders11/32
Decreased appetiteMetabolism and nutrition disorders11/32
AstheniaGeneral disorders10/32
Weight decreasedInvestigations8/32
Pain in extremityMusculoskeletal and connective tissue disorders8/32
InsomniaPsychiatric disorders8/32

Baseline characteristics

Age Continuous
Age Continuous(Years)Axitinib
Mean62.40 ± 15.56
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib
Female15
Male17
08

Study locations

12 sites
  • Pfizer Investigational Site
    Orange, California 92868, United States
  • Pfizer Investigational Site
    Miami Beach, Florida 33140, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02114, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02115, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02215, United States
  • Pfizer Investigational Site
    Clairton, Pennsylvania 15025, United States
  • Pfizer Investigational Site
    Greensburg, Pennsylvania 15601, United States
  • Pfizer Investigational Site
    Johnstown, Pennsylvania 15901, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15232-1305, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15232, United States
  • Pfizer Investigational Site
    Wexford, Pennsylvania 15090, United States
  • Pfizer Investigational Site
    Paris Cedex 13, 75651, France
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 3 years 11 months after primary completion. A results delay was requested in Mar 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2004
First posted
Oct 14, 2004
Start
Dec 2004
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results delay requested
Mar 20, 2009
Results first posted
Mar 30, 2012
Last update
Jun 26, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00094107
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 14, 2004
Start date
Dec 2004
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Mar 30, 2012
Last update
Jun 26, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion